Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioVacSafe Fluad Study
NCT02523287Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Fluzone Trivalent in influenza (4 arms), sponsored by Ghent University Hospital. Primary endpoints: Frequency of local and systemic vaccine-related clinical events up to 28 days, Change from pre-immunisation baseline values in pulse up to 28 days and 18 more. Started Oct 2014; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02523287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523287.